Sanofi
CIK 0001121404 · PARIS, I0 · Quarter end: 2026-06-30 · Filed on: 2026-07-28 · Open the SEC source ↗
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.
$534.0M
2026 Q2
Positions
10
Top-10 ConcentrationHow much of the portfolio sits in the 10 largest holdings. High = concentrated bets.
100.0%
Est. Net Flow (Q)
—
2026 Q2
Top Holdings
MGTX
MeiraGTx Holdings plc
30.9%
INBX
Inhibrx Biosciences, Inc.
20.5%
NVAX
Novavax
12.1%
ANAB
AnaptysBio
10.4%
ODTX
Odyssey Therapeutics Inc.
7.0%
AGMB
Agomab Therapeutics NV
6.8%
MPLT
MapLight Therapeutics Inc.
6.1%
TRAX
First Tracks Biotherapeutics Inc.
3.1%
New / Increased
No prior quarter data
Reduced / Exited
No prior quarter data
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.